06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

Regeneron, bluebird ink multitarget deal for cancer

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
22:43 , Aug 6, 2018 |  BC Extra  |  Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
17:58 , Jul 20, 2018 |  BC Week In Review  |  Company News

Kite looks to Gadeta for gamma delta T cell tech

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences...
20:06 , Jul 19, 2018 |  BC Extra  |  Company News

Kite, Gadeta in gamma delta T cell deal

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences...
00:06 , Jun 28, 2018 |  BC Extra  |  Company News

Management tracks: Arrakis, Astellas

Arrakis Therapeutics Inc. (Waltham, Mass.) founder and CSO Russ Petter is transitioning to Jennifer. The news was announced in a blog post by Chairman and CEO Michael Gilman. "The support for this transition at Arrakis,...
18:21 , May 25, 2018 |  BC Week In Review  |  Financial News

Lava raises €16M for gamma delta T cell platform

Lava Therapeutics B.V. ('s-Hertogenbosch, the Netherlands) raised €16 million ($18.8 million) on May 23 in a series B round led by Gilde Healthcare and Versant Ventures. Also participating were MRL Ventures Fund, Lupus Ventures and...
09:12 , May 23, 2018 |  BC Extra  |  Financial News

Lava raises €16M for gamma delta T cell platform

Lava Therapeutics B.V. ('s-Hertogenbosch, the Netherlands) raised €16 million ($18.8 million) in a series B round led by Gilde Healthcare and Versant Ventures. Also participating were MRL Ventures Fund, Lupus Ventures and Biox Biosciences. Lupus...
00:19 , Mar 7, 2018 |  BC Extra  |  Company News

Management tracks: Alliance, Anika

Alliance Pharma plc (LSE:APH) said CEO John Dawson will step down, effective May 1. He will be succeeded by Deputy CEO Peter Butterfield. The company also said Chairman Andrew Smith has stepped down. Smith is...
18:39 , Jan 18, 2018 |  BC Innovations  |  Emerging Company Profile

Allogeneic expansion

Rather than taking the conventional approach of starting with autologous therapies, Adicet Bio Inc. is building an allogeneic pipeline from the get-go as part of the charge to make γδ T cells for solid and...
00:08 , Dec 2, 2017 |  BioCentury  |  Strategy

Branching out

Decibel Therapeutics Inc. and Regeneron Pharmaceuticals Inc. have embarked on a deal that gives the smaller company a suite of technologies it could not build itself, while giving the big cap a stake in a...